Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
Recruiting · NCT07077512 · Registry updated 2026-01-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Recruiting | Phase 2 | 2026-01-21 | NCT07077512 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fifth Affiliated Hospital of Guangzhou Medical University | 17 |
| Guangzhou Overseas Chinese Hospital,Guangdong | 1 |
| Sun Yat-sen University | 606 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fifth Affiliated Hospital of Guangzhou Medical University | Guangzhou | China | 1 |
| Guangzhou overseas Chinese hospital | Guangzhou | China | 1 |
| Sun Yat-sen Universitiy Cancer Center | Guangzhou | China | 1 |